Clinical and Molecular Hepatology

"Hwi Young Kim"

Reviews

Liver fibrosis, cirrhosis, and portal hypertension

Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis: Ho Soo Chun, A Reum Choe, Minjong Lee, Yuri Cho, Hwi Young Kim, Kwon Yoo, Tae Hun Kim; Clin Mol Hepatol 2021;27(4):535-552.
Published online June 16, 2021; DOI: https://doi.org/10.3350/cmh.2021.0109

Abstract
PDF

Although patients with cirrhosis are known to be in a state of “rebalance” in that pro- and anticoagulant factors increase the risk for both bleeding and thrombosis, the prevalence of portal vein thrombosis (PVT) in patients with cirrhosis can be up to 26%. Therefore, physicians should consider anticoagulation for the prevention and management of PVT in patients with cirrhosis who are at high risk of PVT. Vitamin K antagonist or low molecular weight heparin is suggested as the standard treatment for PVT in cirrhosis. With the advent of new direct-acting oral anticoagulants (DOACs), there is a paradigm shift of switching to DOACs for the treatment of PVT in patients with cirrhosis. However, the safety and efficacy of DOACs in the treatment of PVT was not well-known in patients with cirrhosis. Therefore, this review focused on the current knowledge about the efficacy, safety concerns, and hepatic metabolism of DOACs in patients with cirrhosis and PVT.

Citations

Citations to this article as recorded by

A glycoprotein UGP2A from the medicinal insect Ulomoides dermestoides alleviates deep vein thrombosis via the TLR4/MyD88 signaling pathway
Qun Yu, Caiyi Wang, Yadan Dong, Mingrong Li, Ting Yan, Heng Liu, Chenggui Zhang, Jiapeng Wang, Huai Xiao
International Journal of Biological Macromolecules.2026; 341: 150216. CrossRef
Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival
Madhumita Premkumar, Harish Bhujade, Prerna Sharma, Jasvinder Nain, Jasmina Ahluwalia, Anchal Sandhu, Yogendra Kumar, Sahaj Rathi, Sunil Taneja, Ajay Kumar Duseja, Anand V. Kulkarni, Charanpreet Singh, Shano Naseem, Tanka Karki, Pankaj Gupta, Sreedhara B.
Alimentary Pharmacology & Therapeutics.2025; 61(6): 971. CrossRef
Comprehensive approach to liver cirrhosis treatment: Integrating ayurveda, homeopathy, and allopathy
Debabrata Dash, Palak Kesharwani, Raj Kumar Koiri
Pharmacological Research - Natural Products.2025; 6: 100184. CrossRef
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis
Seema Sharma, Nishant Tiwari, Sampat Singh Tanwar
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(9): 11541. CrossRef
Machine learning models predict coagulopathy in traumatic brain injury patients in ER
Haoyu Wang, Wenying Cao, Jianhuang Huang, Yuxing Feng, Cheng Li
Frontiers in Neurology.2025;[Epub] CrossRef
Effect of Direct Oral Anticoagulants Versus Traditional Anticoagulation in Budd-Chiari Syndrome
Xiaojuan Wu, Lijuan Liang, Jinghong Liu
Clinical and Applied Thrombosis/Hemostasis.2025;[Epub] CrossRef
The relationship between gastroduodenal lesions and coronary heart disease
N. U. Chamsutdinov, Ja. N. Abdulmanapova, N. A. Alieva, K. L. Seydalieva, A. R. Arbukhanova, M. A. Alakhverdieva, Z. M. Magomedova, R. G. Biybolatova
Meditsinskiy sovet = Medical Council.2025; (15): 58. CrossRef
Comparative Effectiveness and Safety of Various Anticoagulation Regimens for Portal Venous Thrombosis in Cirrhosis: A Systematic Review and Network Meta-Analysis
Zain ul Abideen, Muhammad Hassan Waseem, Noor Ul Huda Ramzan, Hamna Raheel, Fariha Hasan, Pawan Kumar Thada, Prasun K. Jalal
Clinical and Applied Thrombosis/Hemostasis.2025;[Epub] CrossRef
Analysis of Related Influencing Factors of Portal Vein Thrombosis After Hepatectomy
ShiGuai Qi, Jie Tao, Xinhua Wu, Xu Feng, Guoying Feng, Zhengrong Shi
Journal of Laparoendoscopic & Advanced Surgical Techniques.2024; 34(3): 246. CrossRef
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis
Chunwei Cheng, Juan Hua, Liang Xiong
Clinical and Applied Thrombosis/Hemostasis.2024;[Epub] CrossRef
Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review
Xiulin Xiao, Wengen Zhu, Qixin Dai
Clinical and Applied Thrombosis/Hemostasis.2024;[Epub] CrossRef
Portal Vein Variations, Clinical Correlation, and Embryological Explanation: A Review Article
Gareema Tyagi, Roshan K Jha
Cureus.2023;[Epub] CrossRef
THE SURGEON'S PERSPECTIVE ON PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS
S.M. Vasyliuk, V.I. Hudyvok, І.R. Labiak, N.M. Pavliuk, V.M. Atamaniuk
Art of Medicine.2023; : 152. CrossRef
Heparins for prevention and treatment of venous thromboembolism in cirrhosis: Research advances
Zhe Li, Wen-Tao Xu, Xiang-Bo Xu, Xing-Shun Qi
World Chinese Journal of Digestology.2022; 30(9): 381. CrossRef
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?
Xiaobing Wang, Liping Chen
Hepatology International.2022; 16(5): 1248. CrossRef
Direct oral anticoagulants (DOACs): From the laboratory point of view
Sandra Margetić, Sandra Šupraha Goreta, Ivana Ćelap, Marija Razum
Acta Pharmaceutica.2022; 72(4): 459. CrossRef

18,077 View
703 Download
12 Web of Science
Crossref

Steatotic liver disease

Recent advances in nonalcoholic fatty liver disease metabolomics: Hwi Young Kim; Clin Mol Hepatol 2021;27(4):553-559.
Published online June 8, 2021; DOI: https://doi.org/10.3350/cmh.2021.0127

Abstract
PDF

The clinical phenotypes of nonalcoholic fatty liver disease (NAFLD) encompass from simple steatosis to nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis or cirrhosis. Liver biopsy has been the standard to diagnose NASH. However, there has been strong need for precise and accurate noninvasive tests because of invasiveness and sampling variability of biopsy. Metabolomics has drawn attention as a promising diagnostic methodology in the field of NAFLD, particularly to unravel metabolic alterations which plays relevant roles in the progression of NASH. There have been numerous metabolomics researches to find new biomarker of NASH in the last decade, fueled by the recent advances in the metabolomics methodology. This review briefly covers recent research advances on the lipidomics, amino acids and bile acid metabolomics regarding continuing attempts to discover relevant biomarkers for NASH.

Citations

Citations to this article as recorded by

Chronotype, serum metabolome, and nonalcoholic fatty liver disease in middle-aged and older adults: Association and potential mediation analyses
Ming-Jun Hu, Xiao-Min Dong, Xue-Li Wang, Bei Yao, Fu Yu, Dan Su, Lu Li, Yong-Liang Zhang, Xin-Min Chu
Experimental Gerontology.2026; 213: 112998. CrossRef
Alisol F 24-acetate attenuated metabolic dysfunction-associated steatohepatitis by targeting the KEAP1/NRF2-mediated macrophage pyroptosis
Zhiwu Dong, Keliang Huang, Weiyi Wu, Lianxiang Xing, Ying Zhang, Xin Zhang, Wenwei Yang, Kewen Zhao
Chinese Medicine.2026;[Epub] CrossRef
Molecular mechanism of geniposide against ANIT-induced intrahepatic cholestasis by integrative analysis of transcriptomics and metabolomics
Junyi Zhang, Yunting Chen, Guangming Luo, Yangjing Luo
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(1): 765. CrossRef
Integration of network pharmacology, UHPLC-Q exactive orbitrap HRMS technique and metabolomics to elucidate the active ingredients and mechanisms of compound danshen pills in treating hypercholesterolemic rats
Shanlan Li, Jin An, Tong Zhang, Guangyun Chen, Zixuan Zhang, Zhuoqian Guo, Ziqi Dai, Xuehao Cheng, Sijin Cheng, Xiaomin Xiong, Nan Wang, Guanghui Jiang, Bing Xu, Haimin Lei
Journal of Ethnopharmacology.2025; 336: 118759. CrossRef
Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals With Type 2 Diabetes Mellitus
Fariba Ahmadizar, Zobair M. Younossi
Journal of Clinical Gastroenterology.2025; 59(1): 36. CrossRef
Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics
Emily Flam, Joel T. Haas, Bart Staels
Atherosclerosis.2025; 400: 119054. CrossRef
Species differences of fatty liver diseases: comparisons between human and feline
Like Ling, Ruilin Li, Mengqiong Xu, Junjie Zhou, Manli Hu, Xin Zhang, Xiao-Jing Zhang
American Journal of Physiology-Endocrinology and Metabolism.2025; 328(1): E46. CrossRef
Untargeted lipidomic analysis of metabolic dysfunction-associated steatohepatitis in women with morbid obesity
Laia Bertran, Jordi Capellades, Sonia Abelló, Cristóbal Richart, Anna Di Sessa
PLOS ONE.2025; 20(3): e0318557. CrossRef
Mechanistic Study of the Deuterium Effect in Chromatographic Separation for Chemical-Tagging Metabolomics and Its Application to Biomarker Discovery in Metabolic Dysfunction-Associated Steatohepatitis
Yugo Akioka, Tomoya Higuchi, Takahiro Takayama, Mayuko Ichimura-Shimizu, Koichi Tsuneyama, Koichi Inoue
Analytical Chemistry.2025; 97(16): 8931. CrossRef
Platycodon grandiflorum Attenuates Non‐Alcoholic Fatty Liver Disease in Rats Through Regulating Inflammatory Response via PPARγ and TLR4/NF‐κB Signaling Pathway
Ming Dang, Jie Zhang, Run‐Xin Ren, Mao‐Mao Fu, Kang‐Jie Li, Huan‐Qing Gao, Qiao Zhang, Jing Wang, Jing Sun, Xiao‐Fei Zhang, Chang‐Li Wang, Meng‐Meng Zhang, Chong‐Bo Zhao
Biomedical Chromatography.2025;[Epub] CrossRef
A plasma metabolome‐derived model predicts severe liver outcomes of nonalcoholic fatty liver disease in the UK Biobank
Xiaoqin Xu, Jiang Li, Yanqi Fu, Jie Li, Wenqi Shen, Xiao Tan, Ningjian Wang, Bin Wang, Yingli Lu
Diabetes, Obesity and Metabolism.2025; 27(9): 4903. CrossRef
Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders
Maria-Zinaida Dobre, Bogdana Virgolici, Ruxandra Cioarcă-Nedelcu
Current Issues in Molecular Biology.2025; 47(7): 565. CrossRef
Association of alpha-1 acid glycoprotein with hepatic steatosis and liver fibrosis among women: a population-based study
Sichang Wang
BMC Gastroenterology.2025;[Epub] CrossRef
Mechanism of Quercetin alleviated E. coli K88-induced Liver Injury in Broilers
Shuaishuai Zhou, Yuxin Fu, Qinglin Yang, Junhong Liu, Yao Li
Poultry Science.2025; 104(11): 105828. CrossRef
Dissecting causal relationships between inflammatory factors, plasma metabolites, and nonalcoholic fatty liver disease: a mediating Mendelian randomization study
Dequan Zhong, Shizhan Deng, Yonggan Dong, Yanan Qian, Sudi Zhu, Mengxue Hu, Meng Liu, Kemeng Tan, Heng Tang
European Journal of Gastroenterology & Hepatology.2025;[Epub] CrossRef
Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease
Ashraf Abbass Basuni, Dina Sweed, Mohammed Fathey Elgazzar, Ashraf Khalil
Egyptian Liver Journal.2024;[Epub] CrossRef
Enhanced hepatic metabolic perturbation of polystyrene nanoplastics by UV irradiation-induced hydroxyl radical generation
Shiyu He, Jingran Wang, Lihong Zhou, Zhen Mao, Xiaodan Zhang, Jin Cai, Peili Huang
Journal of Environmental Sciences.2024; 142: 259. CrossRef
Shenling Baizhu powder alleviates non-alcoholic fatty liver disease by modulating autophagy and energy metabolism in high-fat diet-induced rats
Maoxing Pan, Yuanjun Deng, Yebei Qiu, Dajin Pi, Chuiyang Zheng, Zheng Liang, Jianwei Zhen, Wen Fan, Qingliang Song, Jinyue Pan, Yuanyou Li, Haizhen Yan, Qinhe Yang, Yupei Zhang
Phytomedicine.2024; 130: 155712. CrossRef
Amino Acids during Pregnancy and Offspring Cardiovascular–Kidney–Metabolic Health
You-Lin Tain, Chien-Ning Hsu
Nutrients.2024; 16(9): 1263. CrossRef
Association Between Remnant Cholesterol and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis
Jiake Tang, Ting Tang, Qingwen Yu, Xuhan Tong, Chun Liu, Chen Chen, Siqi Hu, Shenghui Zhang, Yao You, Chunyi Wang, Jie Li, Wen Wen, Juan Chen, Xingwei Zhang, Mingwei Wang, Fan Tong
Metabolic Syndrome and Related Disorders.2024; 22(9): 637. CrossRef
The Liver-Protective Effects of the Essential Oil from Amomum villosum in Tilapia (Oreochromis niloticus): Antioxidant, Transcriptomic, and Metabolomic Modulations
Hongbiao Dong, Xiangbing Zeng, Xiaoting Zheng, Chenghui Li, Junchao Ming, Jiasong Zhang
Antioxidants.2024; 13(9): 1118. CrossRef
Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics
Heng Yuan, Eun-Soo Jung, Soo-Wan Chae, Su-Jin Jung, James W. Daily, Sunmin Park
Nutrients.2024; 16(18): 3061. CrossRef
Schisandrin A alleviates non-alcoholic fatty liver disease by improving liver metabolic disorders and suppressing the GSK3β signaling pathway
Li Zong, Rui Xu, Yunxia Sun, Junjie Qiu, Huihui Tao, Chengyu Shentu, Hongxia Niu, Tengfei Xu, Yuan Zhou
Food Bioscience.2024; 62: 105245. CrossRef
Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease
Diren Beyoğlu, Yury V. Popov, Jeffrey R. Idle
International Journal of Molecular Sciences.2024; 25(23): 12809. CrossRef
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro
Mahmoud A. Shatta, Marwa O. El-Derany, Abdullah A. Gibriel, Hala O. El-Mesallamy
Molecular and Cellular Biochemistry.2023; 478(8): 1689. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
European Journal of Clinical Investigation.2023;[Epub] CrossRef
Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
Georgia Anastasiou, Evangelos Liberopoulos, Ermioni Petkou, Amalia Despoina Koutsogianni, Petros Spyridwnas Adamidis, George Liamis, Evangelia Ntzani, Fotios Barkas
Diagnostics.2023; 13(3): 503. CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Seung Min Lee, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Jung Hwan Yu, Han Ah Lee, Seung Up Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef
Screening strategy for non-alcoholic fatty liver disease
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
Clinical and Molecular Hepatology.2023; 29(Suppl): S103. CrossRef
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong
Clinical and Molecular Hepatology.2023; 29(Suppl): S171. CrossRef
Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification
Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim
Metabolites.2023; 13(3): 444. CrossRef
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Sang Bong Ahn
Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Non-alcoholic fatty liver disease: the pathologist’s perspective
Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Yi-wen Shi, Jian-Gao Fan
Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef
Bile Acid Alterations Characterize the Early Onset and Progression of Nonalcoholic Fatty Liver Disease in Young Mice Fed with High Fat and Fructose Diet
Wenqing Xiang, Ana Liu, Cuifang Xu, Danni Zhang, Wei Li, Yan Ni
Molecular Nutrition & Food Research.2023;[Epub] CrossRef
A lipidomic study: Nobiletin ameliorates hepatic steatosis through regulation of lipid alternation
Xushan Yang, Linye Sun, Dongliang Feng, Yudi Deng, Wenzhen Liao
The Journal of Nutritional Biochemistry.2023; 118: 109353. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD
Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim
Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease
Metin Demirel, Fatmanur Köktaşoğlu, Esin Özkan, Halime Dulun Ağaç, Ayşe Zehra Gül, Rasul Sharifov, Ufuk Sarıkaya, Metin Başaranoğlu, Şahabettin Selek
Scandinavian Journal of Gastroenterology.2023; 58(11): 1344. CrossRef
Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis
Xinzhu Liu, Jiaxuan Wang, Maogang Li, Jiannan Qiu, Xingying Li, Li Qi, Jia Liu, Ping Liu, Guoxiang Xie, Xiaoning Wang
Journal of Gastroenterology and Hepatology.2023; 38(8): 1438. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong
Gut and Liver.2023; 17(4): 610. CrossRef
Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial
Han Ah Lee, Hyeyoung Moon, Yuri Kim, Hye Ah Lee, Hwi Young Kim
Trials.2023;[Epub] CrossRef
Bavachin combined with epimedin B induce idiosyncratic liver injury under immunological stress conditions
Mengmeng Lin, Yingying Li, Bo Cao, Jing Xu, Yujun Zhang, Guohui Li, Xiaohe Xiao, Chunyu Li
Chemico-Biological Interactions.2023; 386: 110774. CrossRef
Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD
Charalambos Fotakis, Ioanna-Panagiota Kalafati, Athina I. Amanatidou, Vasiliki Andreou, Manolis Matzapetakis, Maria Kafyra, Iraklis Varlamis, Maria Zervou, George V. Dedoussis
Frontiers in Endocrinology.2023;[Epub] CrossRef
Genetically predicted plasma levels of amino acids and metabolic dysfunction-associated fatty liver disease risk: a Mendelian randomization study
Jian Zhao, Jing Zeng, Cairong Zhu, Xuechao Li, Dong Liu, Jun Zhang, Fei Li, Giovanni Targher, Jian-Gao Fan
BMC Medicine.2023;[Epub] CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults
Ji-Hee Haam, Yun Kyong Lee, Eunkyung Suh, Young-Sang Kim
Diagnostics.2022; 12(5): 1199. CrossRef
Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
Simona Riccio, Rosa Melone, Caterina Vitulano, Pierfrancesco Guida, Ivan Maddaluno, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa
World Journal of Clinical Pediatrics.2022; 11(3): 221. CrossRef
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
Hepatology Research.2022; 52(12): 975. CrossRef
The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology
Youngseok Lee, Jong-Hoon Kim
Clinical and Molecular Hepatology.2022; 28(4): 706. CrossRef
The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review
Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley
Current Oncology.2022; 30(1): 48. CrossRef
Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics
Yanbo Feng, Han Li, Cong Chen, Hao Lin, Guangyu Xu, He Li, Chunmei Wang, Jianguang Chen, Jinghui Sun
Frontiers in Pharmacology.2021;[Epub] CrossRef

15,921 View
549 Download
58 Web of Science
Crossref

Letter to the Editor

Hepatic neoplasm

Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma: Hwi Young Kim, Jean-François Dufour; Clin Mol Hepatol 2020;26(2):238-239.
Published online March 18, 2020; DOI: https://doi.org/10.3350/cmh.2020.0051

Citations

Citations to this article as recorded by

The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef

7,066 View
70 Download
1 Web of Science
Crossref

Original Articles

Viral hepatitis

Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients: Goh Eun Chung, Eun Ju Cho, Jeong-Hoon Lee, Jeong-ju Yoo, Minjong Lee, Yuri Cho, Dong Hyeon Lee, Hwi Young Kim, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim; Clin Mol Hepatol 2017;23(1):66-73.
Published online February 14, 2017; DOI: https://doi.org/10.3350/cmh.2016.0060

Abstract
PDF

Background/Aims
A recent study reported that entecavir had inferior efficacy in nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients compared to NA-naïve patients. We sought to compare the efficacy of tenofovir disoproxil fumarate (TDF) in NA-experienced and NA-naïve CHB patients.
Methods
We retrospectively enrolled 252 consecutive patients who had a serum hepatitis B virus (HBV) DNA level greater than 2,000 IU/mL at the initiation of TDF treatment and who received TDF for at least 6 months. Complete virologic suppression (CVS) was defined as undetectable serum HBV DNA. We generated a multivariate Cox proportional-hazard model to examine predictive factors that were independently associated with time to CVS.
Results
The mean age of patients was 48.2 years, and the cohort included 181 NA-naïve patients and 71 NA-experienced patients. The median duration of TDF treatment was 14.4 (interquartile range, 9.5-17.8) months. A total of 167 (92.3%) of 181 NA-naïve patients achieved CVS, and 60 (84.5%) of 71 NA-exposed patients achieved CVS. Forty-nine (89.1%) of 55 patients who previously took an NA aside from adefovir and 11 (68.8%) of 16 adefovir-experienced patients achieved CVS. In multivariable analysis, previous adefovir exposure significantly influenced time to CVS (hazard ratio, 0.37; 95% confidence interval, 0.19-0.72; P=0.003), after adjusting for HBeAg positivity, baseline HBV DNA level and cirrhosis.
Conclusions
Tenofovir had inferior efficacy in adefovir-experienced CHB patients compared to NA-naïve patients. The response of patients with previous adefovir exposure to TDF monotherapy should be monitored closely.

Citations

Citations to this article as recorded by

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
Xieer Liang, Qing Xie, Jia Shang, Hong Tang, Min Xu, Qinghua Meng, Jiming Zhang, Pujun Gao, Jifang Sheng, Hao Wang, Jidong Jia, Guiqiang Wang, Shunquan Wu, Jingna Ping, Jinlin Hou
Journal of Gastroenterology and Hepatology.2022; 37(3): 471. CrossRef
Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers
Jung Hun Kim, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo, Eileen L. Yoon, Seong Hee Kang
Antimicrobial Agents and Chemotherapy.2022;[Epub] CrossRef
Clinical effects of NTCP‐inhibitor myrcludex B
Dongliang Cheng, Bing Han, Wei Zhang, Wei Wu
Journal of Viral Hepatitis.2021; 28(6): 852. CrossRef
Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs
Daiki Yamashige, Tetsuya Hosaka, Fumitaka Suzuki, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada
Journal of Gastroenterology.2021; 56(11): 1008. CrossRef
Tenofovir‐based combination therapy or monotherapy for multidrug‐resistant chronic hepatitis B: Long‐term data from a multicenter cohort study
Hyung Joon Yim, Sang Jun Suh, Young Kul Jung, Seong Gyu Hwang, Yeon Seok Seo, Soon Ho Um, Sae Hwan Lee, Young Seok Kim, Jae Young Jang, In Hee Kim, Hyoung Su Kim, Ji Hoon Kim, Young Sun Lee, Eileen L. Yoon, Myeong Jun Song, Jun Yong Park
Journal of Viral Hepatitis.2020; 27(12): 1306. CrossRef
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients
Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon Lee, Jeong-Ju Yoo, Sung Hyun Ahn, Heewoo Sim, Soree Park, Hong Seok Kang, Juhee Won, Yea Na Ha, Gu-Choul Shin, So Young Kwon, Yong Kwang Park, Byeong-Sun Choi, Yun Bin Lee, Nakcheol Jeong, Yohan An, Youn
Journal of Hepatology.2019; 70(6): 1093. CrossRef
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate
In Suk Min, Chang Hun Lee, Ik Sang Shin, Na Eun Lee, Hong Seon Son, Seung Bum Kim, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, In Hee Kim
Gut and Liver.2019; 13(1): 93. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray
Doo Hyun Kim, Hong Seok Kang, Seong-Suk Hur, Seobo Sim, Sung Hyun Ahn, Yong Kwang Park, Eun-Sook Park, Ah Ram Lee, Soree Park, So Young Kwon, Jeong-Hoon Lee, Kyun-Hwan Kim
Gut and Liver.2018; 12(3): 331. CrossRef
Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?
Sung Won Chung, Young Chang, Hyo Young Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
Yun Bin Lee, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2017; 23(3): 219. CrossRef

13,785 View
172 Download
12 Web of Science
Crossref

Viral hepatitis

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study: Dae Won Jun, Byung Ik Kim, Yong Kyun Cho, Hong Ju Kim, Young Oh Kwon, Soo Young Park, Sang Young Han, Yang Hyun Baek, Yong Jin Jung, Hwi Young Kim, Won Kim, Jeong Heo, Hyun Young Woo, Seong Gyu Hwang, Kyu Sung Rim, Jong Young Choi, Si Hyun Bae, Young Sang Lee, Young Suck Lim, Jae Youn Cheong, Sung Won Cho, Byung Seok Lee, Seok Hyun Kim, Joo Hyun Sohn, Tae Yeob Kim, Yong Han Paik, Ja Kyung Kim, Kwan Sik Lee; Clin Mol Hepatol 2013;19(2):165-172.
Published online June 27, 2013; DOI: https://doi.org/10.3350/cmh.2013.19.2.165

Abstract
PDF

Background/Aims

Carnitine and vitamin complex (Godex®) is widely used in patients with chronic liver disease who show elevated liver enzyme in South Korea. The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients.

Methods

130 treatment-naïve patients with CHB were enrolled from 13 sites. The patients were randomly selected to the entecavir and the complex of entecavir and carnitine. The primary endpoint of the study is ALT normalization level after 12 months.

Results

Among the 130 patients, 119 patients completed the study treatment. The ALT normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001). ALT normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019). The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was. Quantification of HBsAg level was not different from the monotherapy to combination at 12 months. Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment.

Conclusions

ALT normalization rate was higher in carnitine complex combination group than entecavir group in CHB. Combination group was faster than entecavir mono-treatment group on ALT normalization rate. HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment.

Citations

Citations to this article as recorded by

Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials
Palak K. Parikh, Nisha H. Parikh, Mahalakshmi B, Ketan M. Ranch, Sai H.S. Boddu, Jayachandra Babu R, Amit K. Tiwari
Arabian Journal of Chemistry.2023; 16(8): 105013. CrossRef
Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients
Hyung Joon Yim, Won Kim, Sang Hoon Ahn, Young Kul Jung, Soon Ho Um, Joo Hyun Sohn, Jae Young Jang, Dong Joon Kim, Eun‐Sook Park, So‐Young Jin, Kyun‐Hwan Kim
Journal of Gastroenterology and Hepatology.2022; 37(2): 378. CrossRef
Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center–Related Immune Cells
Shuqin Gu, Weibin Wang, Guofu Ye, Chengcong Chen, Yang Zhou, Ling Guo, Shihong Zhong, Xiaoyi Li, Xin Fu, Chunhua Wen, Libo Tang, Jian Sun, Jinlin Hou, Yongyin Li
The Journal of Infectious Diseases.2022; 225(11): 1955. CrossRef
Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study
Eileen L. Yoon, Sang Bong Ahn, Dae Won Jun, Yong Kyun Cho, Do Seon Song, Jae Yoon Jeong, Hee Yeon Kim, Young Kul Jung, Myeong Jun Song, Sung Eun Kim, Hyoung Su Kim, Soung Won Jeong, Sang Gyune Kim, Tae Hee Lee
The Korean Journal of Internal Medicine.2022; 37(4): 757. CrossRef
Impact of l-Carnitine Supplementation on Liver Enzyme Normalization in Patients with Chronic Liver Disease: A Meta-Analysis of Randomized Trials
Hyunwoo Oh, Chan Hyuk Park, Dae Won Jun
Journal of Personalized Medicine.2022; 12(7): 1053. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Prolonged Use of Carnitine-Orotate Complex (Godex®) Is Associated with Improved Mortality: A Nationwide Cohort Study
Kye-Yeung Park, Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
Journal of Personalized Medicine.2022; 12(12): 1970. CrossRef
Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update
Na Li, Hui Zhao
Frontiers in Medicine.2021;[Epub] CrossRef
High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection
Shuqin Gu, Xin Fu, Guofu Ye, Chengcong Chen, Xiaoyi Li, Shihong Zhong, Libo Tang, Haitao Chen, Deke Jiang, Jinlin Hou, Yongyin Li
Frontiers in Immunology.2021;[Epub] CrossRef
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B
Jeong Eun Song, Jun Yong Park
Expert Opinion on Pharmacotherapy.2021; 22(18): 2427. CrossRef
Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway
Jung-Hee Hong, Moon-Kyu Lee
Diabetes & Metabolism Journal.2021; 45(6): 933. CrossRef
Does l-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials
Farzaneh Pirmadah, Nahid Ramezani-Jolfaie, Mohammad Mohammadi, Nasir Talenezhad, Cain C. T. Clark, Amin Salehi-Abargouei
European Journal of Nutrition.2020; 59(5): 1767. CrossRef
The protective role of l-carnitine against 1st- and 2nd-generation antihistamine-induced liver injury in mice
Rania A. Abdel-Emam, Esraa A. Ahmed, Marwa F. Ali
Comparative Clinical Pathology.2020; 29(1): 213. CrossRef
Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Journal of Korean Medical Science.2020;[Epub] CrossRef
Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials
Esmaeil Yousefi Rad, Elham Eslampour, Ebrahim Falahi, Mahnaz Mardani, Azita Hekmatdoost, Omid Asbaghi, Somayeh Saboori
Indian Journal of Gastroenterology.2019; 38(6): 470. CrossRef
L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi,
Hepatology Communications.2018; 2(8): 910. CrossRef
Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature
Rachael R. Schulte, Manasi V. Madiwale, Allyson Flower, Jessica Hochberg, Michael J. Burke, Jennifer L. McNeer, Adam DuVall, Archie Bleyer
Leukemia & Lymphoma.2018; 59(10): 2360. CrossRef
Anti-adipogenic and antiviral effects ofl-carnitine on hepatitis C virus infection
Yoko Tsukuda, Goki Suda, Seiji Tsunematsu, Jun Ito, Fumiyuki Sato, Katsumi Terashita, Masato Nakai, Takuya Sho, Osamu Maehara, Tomoe Shimazaki, Megumi Kimura, Kenichi Morikawa, Mitsuteru Natsuizaka, Koji Ogawa, Shunsuke Ohnishi, Makoto Chuma, Naoya Sakamo
Journal of Medical Virology.2017; 89(5): 857. CrossRef
Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition
Qianying Chen, Hongzhu Chen, Wenjie Wang, Jiali Liu, Wenyue Liu, Ping Ni, Guowei Sang, Guangji Wang, Fang Zhou, Jingwei Zhang
European Journal of Pharmaceutical Sciences.2017; 106: 313. CrossRef
A Case of Therapeutic Laser for Suggested Drug Induced Liver Injury Patient during Treatment of Korean Medicine
Kyeong-Tae Lim, Byung-Cheul Shin, Eui-Hyoung Hwang, In Heo, Byung-Jun Kim, Kwang-Ho Heo
Journal of Korean Medicine Rehabilitation.2016; 26(3): 183. CrossRef
Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition
Zhongqi Dong, Sean Ekins, James E. Polli
European Journal of Pharmaceutical Sciences.2015; 66: 1. CrossRef
Comparison on the Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid in Patients with Abnormal Alanine Aminotransferase: Multicenter, Double-blinded, Randomized, Active-controlled Clinical Trial
Sae Hwan Lee, Gab Jin Cheon, Hong Soo Kim, Young Don Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
The Korean Journal of Gastroenterology.2014; 64(1): 31. CrossRef